Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability*

Cell survival is regulated by a signaling network driven by the activity of protein kinases; however, determining the contribution that each kinase in the network makes to such regulation remains challenging. Here, we report a computational approach that uses mass spectrometry-based phosphoproteomics data to rank protein kinases based on their contribution to cell regulation. We found that the scores returned by this algorithm, which we have termed kinase activity ranking using phosphoproteomics data (KARP), were a quantitative measure of the contribution that individual kinases make to the signaling output. Application of KARP to the analysis of eight hematological cell lines revealed that cyclin-dependent kinase (CDK) 1/2, casein kinase (CK) 2, extracellular signal-related kinase (ERK), and p21-activated kinase (PAK) were the most frequently highly ranked kinases in these cell models. The patterns of kinase activation were cell-line specific yet showed a significant association with cell viability as a function of kinase inhibitor treatment. Thus, our study exemplifies KARP as an untargeted approach to empirically and systematically identify regulatory kinases within signaling networks.

[1]  C. Marshall,et al.  Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells , 1994, Cell.

[2]  S. Fields,et al.  Global analysis of phosphorylation and ubiquitylation cross-talk in protein degradation , 2013, Nature Methods.

[3]  Evan O. Paull,et al.  Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer , 2016, Cell.

[4]  B. Kholodenko,et al.  PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. , 2010, Cellular signalling.

[5]  J. Gribben,et al.  Empirical inference of circuitry and plasticity in a kinase signaling network , 2015, Proceedings of the National Academy of Sciences.

[6]  B. Kuster,et al.  Confident Phosphorylation Site Localization Using the Mascot Delta Score , 2010, Molecular & Cellular Proteomics.

[7]  Chih-Chiang Tsou,et al.  IDEAL-Q, an Automated Tool for Label-free Quantitation Analysis Using an Efficient Peptide Alignment Approach and Spectral Data Validation* , 2009, Molecular & Cellular Proteomics.

[8]  D. Lauffenburger,et al.  Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction , 2009, Molecular systems biology.

[9]  Gary D Bader,et al.  A draft map of the human proteome , 2014, Nature.

[10]  Hongmao Sun,et al.  Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[12]  J. Saez-Rodriguez,et al.  Large-scale models of signal propagation in human cells derived from discovery phosphoproteomic data , 2015, Nature Communications.

[13]  C. C. Santini,et al.  Unmasking Determinants of Specificity in the Human Kinome , 2015, Cell.

[14]  S. Joel,et al.  Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells , 2013, Science Signaling.

[15]  M. Waterfield,et al.  Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Elledge,et al.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. , 1992, Science.

[17]  P. Cutillas,et al.  Characterization of a TiO2 enrichment method for label-free quantitative phosphoproteomics , 2011, Methods.

[18]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[19]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[20]  Tony Pawson,et al.  Comparative Analysis Reveals Conserved Protein Phosphorylation Networks Implicated in Multiple Diseases , 2009, Science Signaling.

[21]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[22]  P. Bork,et al.  Systematic Discovery of In Vivo Phosphorylation Networks , 2007, Cell.

[23]  P. Cohen,et al.  The role of protein phosphorylation in neural and hormonal control of cellular activity , 1982, Nature.

[24]  B. Vanhaesebroeck,et al.  Quantitative Profile of Five Murine Core Proteomes Using Label-free Functional Proteomics*S , 2007, Molecular & Cellular Proteomics.

[25]  Jihye Kim,et al.  Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data , 2015, Bioinform..

[26]  Pedro R Cutillas,et al.  A Self-validating Quantitative Mass Spectrometry Method for Assessing the Accuracy of High-content Phosphoproteomic Experiments* , 2010, Molecular & Cellular Proteomics.

[27]  C. Bakal,et al.  Phosphorylation Networks Regulating JNK Activity in Diverse Genetic Backgrounds , 2008, Science.

[28]  R. Linding,et al.  Simplistic pathways or complex networks? , 2010, Current opinion in genetics & development.

[29]  Pedro de Atauri,et al.  Metabolic control analysis in drug discovery and disease , 2002, Nature Biotechnology.

[30]  Joel Selkrig,et al.  An atlas of human kinase regulation , 2016, Molecular Systems Biology.

[31]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[32]  A. Heck,et al.  Single-step Enrichment by Ti4+-IMAC and Label-free Quantitation Enables In-depth Monitoring of Phosphorylation Dynamics with High Reproducibility and Temporal Resolution * , 2014, Molecular & Cellular Proteomics.

[33]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[34]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[35]  B. Kuster,et al.  Mass-spectrometry-based draft of the human proteome , 2014, Nature.

[36]  Y. Mechref,et al.  ProteinQuant Suite: a bundle of automated software tools for label-free quantitative proteomics. , 2008, Rapid communications in mass spectrometry : RCM.

[37]  S. Gygi,et al.  A site-specific, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectrometry , 2009, Proceedings of the National Academy of Sciences.

[38]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[39]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[40]  John G Doench,et al.  Kinase requirements in human cells: I. Comparing kinase requirements across various cell types , 2008, Proceedings of the National Academy of Sciences.

[41]  P. Bork,et al.  Evolution and functional cross‐talk of protein post‐translational modifications , 2013, Molecular systems biology.

[42]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[43]  Jürgen Cox,et al.  IKAP: A heuristic framework for inference of kinase activities from Phosphoproteomics data , 2016, Bioinform..